Introduction {#s1}
============

The mitochondrial calcium uniporter is a highly selective multi-subunit Ca^2+^ channel of the inner mitochondrial membrane that serves as the major conduit for uptake of Ca^2+^ by mitochondria and controls ATP production in response to cytosolic Ca^2+^ signals ([@bib15]; [@bib21]; [@bib36]; [@bib39]). The uniporter is one of the most selective Ca^2+^ channels known and it is only activated once cytosolic Ca^2+^ levels reach a threshold (of approximately 0.4--3 μM) ([@bib7]; [@bib23]; [@bib26]; [@bib30]; [@bib42]). These properties, Ca^2+^ selectivity and block of ion permeation under resting conditions, are fundamentally important for preventing mitochondrial Ca^2+^ overload and for maintaining the electromotive force used for ATP production because potassium and other cations outnumber Ca^2+^ by more than one million to one in the cytosol. The protein MCU constitutes the pore of the uniporter through which Ca^2+^ ions flow and EMRE, a small transmembrane protein that associates with MCU, is necessary for Ca^2+^ uptake in metazoan organisms ([@bib4]; [@bib5]; [@bib8]; [@bib24]; [@bib52]). Ca^2+^-dependent control is conferred by proteins that are unique to the uniporter − heterodimers of MICU1-MICU2 in most cells and of MICU1-MICU3 in neurons ([@bib2]; [@bib17]; [@bib20]; [@bib40]; [@bib41]; [@bib42]; [@bib44]; [@bib48]). The activity of the uniporter is further tuned by interactions with MCUR1 ([@bib6]; [@bib29]; [@bib57]) and the MCU-like protein MCUb ([@bib50]). The molecular mechanism by which the MICU1-MICU2 and MICU1-MICU3 heterodimers regulate the channel is a matter of intense study ([@bib7]; [@bib16]; [@bib17]; [@bib20]; [@bib18]; [@bib35]; [@bib40]; [@bib41]; [@bib42]; [@bib44]; [@bib47]; [@bib48]). Multiple models for this regulation have been proposed but issues as fundamental as the stoichiometry between the heterodimers and the channel remain unclear.

Studies have resolved that MICU1-MICU2 heterodimers reside in the intermembrane space (IMS) where they regulate the uniporter by responding to \[Ca^2+^\]~IMS ~([@bib20]; [@bib40]; [@bib48]). \[Ca^2+^\]~IMS~, which closely follows the cytosolic Ca^2+^ concentration due to the permeability of the outer mitochondrial membrane, is sensed by EF-hand motifs in each protein. At the \~100 nM resting level of \[Ca^2+^\]~cytosol~, MICU1-MICU2 and MICU1-MICU3 heterodimers prevent ion conduction through the channel, and they permit it when Ca^2+^ levels rise ([@bib7]; [@bib17]; [@bib20]; [@bib26]; [@bib30]; [@bib34]; [@bib40]; [@bib41]; [@bib42]; [@bib47]). While structures of MICU1-3 and MCU-EMRE components have been determined ([@bib19]; [@bib38]; [@bib60]; [@bib58]; [@bib59]; [@bib61]; [@bib62]), it is unclear how MICU proteins interact with the channel and the mechanism by which they confer Ca^2+^-dependent control to the channel is enigmatic. Further it is not known why MICU1, in particular, is necessary among MICU1-3 for regulating the channel ([@bib20]; [@bib40]; [@bib41]; [@bib42]; [@bib62]). Here, we present a 3.3 Å resolution cryo-EM structure of the MCU-EMRE-MICU1-MICU2 assembly, hereafter referred to as the holocomplex, under resting \[Ca^2+^\] conditions. Together with functional data and a structure of a Ca^2+^-bound MICU1-MICU2 complex, the work reveals a molecular basis for Ca^2+^-dependent control of the uniporter and the unique role of MICU1 in this process.

Results {#s2}
=======

Structure determination of the MCU-EMRE-MICU1-MICU2 holocomplex {#s2-1}
---------------------------------------------------------------

The ability of human MICU1 to bind MCU channels from lower-eukaryote organisms ([@bib47]) and our ability to obtain high-resolution structures of the metazoan MCU-EMRE channel complex from the red flour beetle, Tribolium castaneum, (*Tc*MCU-EMRE) ([@bib60]) motivated us to pursue a cryo-EM structure of *Tc*MCU-EMRE in complex with human MICU1-MICU2. The amino acids facing the IMS, where MICU1-MICU2 resides, are identical between human and beetle MCU/EMRE and adopt analogous conformations in structures of the human and beetle channels ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

A holocomplex sample that was suitable for structure determination required meticulous formulation. An MCU-EMRE subcomplex was prepared by coexpressing *Tc*MCU and *Tc*EMRE in mammalian cells, purifying the *Tc*MCU-EMRE assembly, and reconstituting it into lipid nanodiscs that include the mitochondrial lipid cardiolipin. Cardiolipin was included because we recently identified that this lipid is important for the function of the uniporter ([@bib60]). We previously observed that a symmetry mismatch between the fourfold symmetric IMS surface of the channel and the asymmetric N-terminal domain (NTDs) in metazoan MCU channels can be a hindrance for high-resolution cryo-EM studies ([@bib3]; [@bib60]). Because the NTD is dispensable for mitochondrial Ca^2+^ uptake ([@bib3]; [@bib33]; [@bib60]; [@bib59]), we removed this domain for high-resolution structural studies. We have recently shown that the *Tc*MCU and *Tc*EMRE constructs used for structural analysis (*Tc*MCU~ΔNTD~ and *Tc*EMRE coexpressed) catalytze Ca^2+^ uptake into human mitochondria ([@bib60]).

In cells, a disulfide bond formed between flexible C-terminal regions of MICU1 and MICU2 helps stabilize the heterodimer ([@bib19]; [@bib40]; [@bib45]). To mimic this condition and discourage the previously observed tendency of purified MICU1 and MICU2 to form homo-oligomers at the high protein concentrations needed for structural studies ([@bib19]; [@bib40]; [@bib58]; [@bib61]; [@bib62]), we expressed MICU1 and MICU2 as a single polypeptide with a linker connecting the two subunits. A further motivation for this approach was the expectation that a MICU1-MICU2 concatemer would facilitate interpretation of the cryo-EM data, as the sample might otherwise contain mixtures of homo- and heterodimers that could be difficult to distinguish computationally. By combining the purified MICU1-MICU2 and MCU-EMRE-nanodisc assemblies we obtained a monodisperse holocomplex sample that was used for cryo-EM analysis ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).

Cryo-EM data were collected using a low (\<1 nM) concentration of Ca^2+^ in order to investigate the resting state of the holocomplex. From a large dataset containing approximately 17 million particle images, single particle analysis indicated that most channels were associated with one MICU1-MICU2 heterodimer ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}). Images containing one MICU1-MICU2 heterodimer per channel yielded a 3D reconstruction of the holocomplex at 3.3 Å resolution ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}, [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). Two MICU1-MICU2 complexes were observed in approximately 2% of channel assemblies ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}, as assessed from 2D class averages of side views). This subset of data yielded a \~ 10 Å resolution 3D reconstruction ([Figure 1---figure supplement 4C](#fig1s4){ref-type="fig"}). In it, one MICU1-MICU2 heterodimer associates with the MCU/EMRE channel in the same manner as in the high-resolution structure. Density for the second MICU1-MICU2 heterodimer is considerably weaker and positioned to the side, next to the channel, where it might interact with the lipid nanodisc. This 3D reconstruction and the 2D class averages, which display blurring of the second heterodimer ([Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}), indicate that the second one does not have a discrete binding location. Except where noted, the discussion that follows pertains to the high-resolution structure of the holocomplex that contains one MICU1-MICU2 heterodimer. The cryo-EM density of this structure is well defined, especially within the TMD and MICU1 regions, which have the highest local resolution (\~3.0 Å, [Figure 1---figure supplement 5C](#fig1s5){ref-type="fig"}). The constructed atomic model has good stereochemistry and excellent agreement with the cryo-EM density ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}, and [Table 1](#table1){ref-type="table"}).

###### Data collection, refinement, and validation statistics.

  ----------------------------------------------------------------------------------------------------
                                     Holocomplex at low \[Ca^2+^\]\   Ca^2+^-bound MICU1-MICU2\
                                     PDB: 6XQN\                       PDB: 6XQO\
                                     EMDB: EMD-22290                  EMDB: EMD-22291
  ---------------------------------- -------------------------------- --------------------------------
  Data collection and processing                                      

  Microscope                         FEI Titan Krios (at MSKCC)       FEI Titan Krios (at MSKCC)

  Camera                             Gatan K3                         Gatan K3

  Magnification                      22,500×                          22,500×

  Voltage (kV)                       300                              300

  Electron exposure (e^--^/Å^2^)     71                               71

  Defocus range (μm)                 −1.0 \~ −3.0                     −0.8 \~ −2.3

  Pixel size (Å)                     1.064 (0.532)\*                  1.064 (0.532)\*

  Software                           RELION 3.0, cryoSPARC v2         RELION 3.0, cryoSPARC v2

  Symmetry imposed                   C1                               C1

  Initial particle images (no.)      17,440,131                       4,397,598

  Final particle images (no.)        350,160                          115,687

  Overall map resolution (Å)\        3.3                              3.1
  FSC threshold 0.143                                                 

  Local map resolution range (Å)     3.0--5.0                         2.8--5.0

  Refinement                                                          

  Software                           Phenix 1.13 real-space-refine    Phenix 1.13 real-space-refine

  Initial model used (PDB code)      N/A                              N/A

  Model resolution (Å)\              3.6                              3.5
  FSC threshold 0.5                                                   

  Map sharpening *B* factor (Å^2^)   −77                              −38

  Model composition                                                   

  Non-hydrogen atoms                 9433                             4225

  Protein residues                   1290                             566

  Ligands                            1 (Calcium ion)                  4 (Calcium ions)

  Water                              0                                0

  *B* factors (Å^2^)                                                  

  Protein                            124.29                           88.3

  Ligand                             70.1                             94.9

  R.m.s. deviations                                                   

  Bond lengths (Å)                   0.006                             0.004

  Bond angles (°)                    1.027                            0.569

  Validation                                                          

  MolProbity score                   1.85                             2.25

  Clashscore                         7.13                             10.75

  Ramachandran plot                                                   

  Favored (%)                        97.45                            95.65

  Allowed (%)                        2.55                             4.35

  Disallowed (%)                     0.0                              0.0

                                                                      \*Super-resolution pixel size.
  ----------------------------------------------------------------------------------------------------

![Cryo-EM reconstruction of the holocomplex.\
(**A**) 2D class averages showing side-views of complexes with one or two MICU1-MICU2 heterodimers associated (top and bottom panels, respectively). (**B--E**) Cryo-EM reconstruction of the holocomplex, shown in orthogonal views. Densities are colored accordingly: MCU (yellow), EMRE (orange), MICU1 (green), MICU2 (blue), and nanodisc (semitransparent gray). Numbers in (**E**) represent the locations of EMRE subunits. The location of where EMRE 4 would be expected to bind is indicated by parentheses (**D--E**).](elife-59991-fig1){#fig1}

Overall structure of the holocomplex {#s2-2}
------------------------------------

MICU1 and MICU2 associate as a heterodimer and bind to the surface of the channel at the IMS entrance of its pore ([Figure 2](#fig2){ref-type="fig"}). Interactions with the channel are mediated solely by MICU1; MICU2 makes no visible contacts with MCU or EMRE. As in cryo-EM and X-ray structures of fungal MCU and metazoan MCU-EMRE channel complexes without MICU1-MICU2 ([@bib3]; [@bib10]; [@bib32]; [@bib60]; [@bib59]; [@bib63]), the pore comprises a single ion conduction pathway through the TMD that is surrounded by four MCU subunits. EMRE subunits, located at the periphery of the TMD, consist of a single transmembrane helix flanked by short N- and C-terminal disordered regions. The conformation of the pore is indistinguishable from that observed in a cryo-EM structure of *Tc*MCU-EMRE without MICU1-MICU2 ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [@bib60]), which suggests that unlike gating conformational changes in many other ion channels, control by MICU1-MICU2 is not accomplished through motions of pore-lining helices.

![Architecture of the holocomplex.\
(**A and B**) Cartoon representations of the holocomplex, colored as in [Figure 1](#fig1){ref-type="fig"}, and shown with semitransparent surfaces. Gray bars represent approximate boundaries of the hydrophobic core of the membrane. A Ca^2+^ion in the E ring is drawn as a purple sphere. The pore (semitransparent gray surface) is depicted as the minimal radial distance from its center to the nearest van der Waals protein contact. (**C**) Pore dimensions in structures of *Tc*MCU-EMRE with and without MICU1-MICU2 (red and blue, respectively). A dashed line indicates the radius of a hydrated Ca^2+^ ion.](elife-59991-fig2){#fig2}

The structure of the holocomplex provides the most well-defined density to date for the ion-selectivity filter, which is formed by a fourfold assembly of the WDXXEP signature sequences of MCU subunits ([Figure 1---figure supplement 5E](#fig1s5){ref-type="fig"}). The 'D' and 'E' residues of this motif (Asp 261 and Glu 264) form two rings of acidic amino acids that line the pore of the channel and can coordinate Ca^2+^ through water-mediated ('D' ring) or direct interactions ('E' ring) ([@bib3]; [@bib10]; [@bib32]; [@bib60]; [@bib59]; [@bib63]). Strong density that we assign as Ca^2+^ on the basis of its coordination and analogy to other structures of MCU is present within the 'E' ring ([Figure 1---figure supplement 5E](#fig1s5){ref-type="fig"}). Its presence under conditions of \<1 nM Ca^2+^ identifies this site as the high-affinity (*K~d~* ≤2 nM) Ca^2+^ binding site previously postulated from electrical recordings made from mitoplasts that is thought to contribute to the channel's high selectivity for Ca^2+ ^([@bib23]). MICU1-MICU2 binding does not displace Ca^2+^ from this site. The 'D' ring is directly coordinated by MICU1, and possibly because of this and/or the low concentration of Ca^2+^ in the sample, density for Ca^2+^ is not observed in this site. Aside from coordination of the 'D' ring, the ion conduction pathway is indistinguishable from the unliganded conformation ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [Figure 2C](#fig2){ref-type="fig"}).

Three EMRE subunits are observed at the periphery of the TMD (EMRE 1--3). Density for a fourth, like that observed in structures without MICU1-MICU2 ([@bib60]; [@bib59]), is conspicuously absent ([Figure 1D and E](#fig1){ref-type="fig"}). MICU1 interacts with only EMRE 1, which has the most well-defined density ([Figure 1B--D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 5D](#fig1s5){ref-type="fig"}). EMRE 2 and 3 adopt the same conformation as EMRE 1, which is the same as the one observed without MICU1-MICU2, in which each EMRE transmembrane helix is positioned approximately 45 ° from the membrane normal and interacts with TM1 of an adjacent MCU subunit ([Figure 2A--B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [@bib60]). MICU1-MICU2 is positioned \~15 Å above where EMRE 4 would be located ([Figure 1D,E](#fig1){ref-type="fig"}). It is possible that interactions between EMRE 4 and MICU1-MICU2, perhaps involving the disordered acidic C-terminal tail of EMRE ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), may destabilize binding of this subunit. In support of this hypothesis, nanodisc density is wider in the vicinity of where EMRE 4 would be positioned ([Figure 1D](#fig1){ref-type="fig"}), which suggests that it may be present within the nanodisc but displaced from the surface of MCU.

A uniporter interaction domain and its receptor site {#s2-3}
----------------------------------------------------

MICU1 contains three domains ([@bib58]): an N-lobe and a C-lobe, which contain its Ca^2+^-binding sites, and an N-terminal domain, which we name the uniporter interaction domain (UID) ([Figure 3A](#fig3){ref-type="fig"}). The UID mediates all observed interactions with the channel. The UID comprises three α-helices (α1, α2, α3) and a small β-sheet formed by strands β1, β2 and β3 ([Figure 3A](#fig3){ref-type="fig"}). Residues on α1 and α2 and a tight turn connecting these helices at Pro 124 directly contact the IMS surface of the channel ([Figure 3D,F--G](#fig3){ref-type="fig"}).

![The UID and its receptor site.\
(**A**) Domain architecture of MICU1. Cartoon representation colored according to subdomains. Spheres indicate the Cα positions of amino acids that would bind Ca^2+^ in EF-hands EF1 and EF4. (**B**) The UID-receptor interface. A semitransparent surface-cartoon rendition of MCU and EMRE is shown, viewed from the IMS. An outline marks the boundaries of the interface of the UID with the channel. α1 and α2 of the UID are depicted as green ribbons. (**C**) Close up view of the receptor site, with residues that interact with the UID drawn as sticks. (**D**) Cryo-EM density and interactions at the IMS mouth of the pore. The interface region between MICU1 and the D ring is shown (MICU1, green; MCU, yellow), with density depicted as a semitransparent surface. Dashed lines indicate hydrogen bonds. (**E**) Mutagenesis of the UID and the effect on mitochondrial Ca^2+^ uptake. The indicated mutants of human MICU1, made in the background of disrupted EF-hand domains (EF), were transiently expressed in MICU1 knockout cells and uptake was quantified relative to wild type (WT) MICU1 and disrupted EF-hand (EF) controls. Western blots demonstrate expression. '-ve' indicates untransfected cells. (mean ±s.d., independent experiments: n = 6 for WT and EF controls, and n = 3 for the remainder. Student's t-Test *p*-values for mutants relative to the EF construct, calculated using the two-tailed distribution with unequal variance method, are listed). (**F and G**) Views showing UID-receptor site interactions (sticks). MICU1 residues are in italics.](elife-59991-fig3){#fig3}

The binding of the UID identifies a receptor for MICU1 on the surface of the channel ([Figure 3B and C](#fig3){ref-type="fig"}). The receptor is relatively flat and spans three MCU subunits and one EMRE subunit. The amino acids comprising it (MCU residues: Trp 255~B~, Tyr 258~A&B~, Ser 259~B~, Asp 261~A,B&D~, and Ile 262~A&B~, and EMRE residue Leu 92, [Figure 3C](#fig3){ref-type="fig"}) are conserved among metazoan channels and are identical between human and beetle channels ([Figure 1---figure supplement 1A--B](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Apart from the absence of EMRE 4, the conformation of the receptor site is indistinguishable from the unliganded conformations of both beetle and human MCU-EMRE complexes ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}; [@bib60]; [@bib59]).

The α1 helix, which is the N-terminal end of the ordered region of MICU1, is positioned horizontally on the receptor, where it contacts one EMRE subunit (EMRE 1) and two MCU subunits through a collection of van der Waals interactions and hydrogen bonds ([Figure 3B,F--G](#fig3){ref-type="fig"}). The interacting residues on α1 (Phe 106, Arg 107, Lys 110, Val 111, Tyr 114, Arg 117, and Tyr 121) are identical in beetle MICU1 and conserved among animals ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).

A hydrophobic interaction between Phe 106 of α1 and the IMS end of EMRE's transmembrane helix at Leu 92, which is also highly conserved ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), comprises the only contact observed between MICU1 and EMRE ([Figure 3G](#fig3){ref-type="fig"}). Although not visible in the density, MICU1 and EMRE may also interact electrostatically -- an acidic C-terminal region of EMRE and a basic region preceding α1, which are disordered, have been implicated in binding ([@bib16]; [@bib56]) and would be in close proximity. A nearby conserved basic surface of MICU1 may be another point of contact for the acidic tail of EMRE ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

The mouth of the pore is coordinated by Lys 126 and Arg 129 from α2, and Ser 122 of the α1-α2 turn through a network of hydrogen bonds that involves three of the four MCU-Asp 261 residues of the 'D' ring ([Figure 3D,F](#fig3){ref-type="fig"}). This confirms the previous hypothesis that the 'D' ring is involved in MICU1 binding ([@bib35]; [@bib47]). The MICU1 residues participating in the hydrogen-bonding network (Tyr 114, Ser 122, Asp 125, Lys 126, Arg 129, and Asp 169) are conserved ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), but none were previously predicted to mediate interactions with the channel ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).

To assess the function of the interacting residues and to gauge their importance and relevance for control of the full-length human MCU-EMRE channel, we evaluated mitochondrial Ca^2+^ uptake when wild type and mutant MICU1 proteins were expressed in human MICU1 knockout cells. As expected, robust mitochondrial Ca^2+^ uptake was observed when wild type MICU1 was expressed and uptake was suppressed by mutations within the Ca^2+^-binding EF-hands of MICU1 that cause it to constitutively inhibit the channel ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}; [@bib20]). Residues that were observed to interact with MCU or EMRE relieve this inhibition when mutated to alanine. This includes not only Lys 126 and Arg 129 of MICU1 that interact with the 'D' ring but also amino acids that interact with MCU and EMRE at a distance from the pore (e.g. Phe 106, Arg 117, and Tyr 121). Lys 126 seems particularly crucial -- a single K126A mutation essentially eliminates inhibition by MICU1. These studies verify the structurally observed interaction and indicate its importance for control of the full-length human channel.

The regions of the UID that interact with the channel are absent in MICU2 or MICU3 ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The α1 helix, the conserved Pro 124 in the bend between α1 and α2, and residues that interact with the 'D' ring are unique to MICU1. This explains why MICU1 is distinct from MICU2 and MICU3 in its ability to interact with MCU/EMRE, and it explains the observation that MICU2 and MICU3 have non-redundant roles in comparison to MICU1 in the regulation of the channel ([@bib20]; [@bib40]; [@bib41]; [@bib42]; [@bib62]).

The interaction with the pore is reminiscent of the interaction between μ-conotoxin KIIIA, a small pore-blocking peptide toxin found in the venom of a cone snail, with the extracellular surface of the neuronal Na~v~1.2 channel ([@bib37]; [@bib64]; [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}). A short α-helical region of the toxin lies horizontally at the entrance of the pore of Na~v~1.2, in a similar manner to the binding of the α2 helix of MICU1 with the uniporter. As in the UID-uniporter interface, an arginine and a lysine residue that are separated by one turn of the toxin's α-helix coordinate acidic amino acids at the entrance of the selectivity filter ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}). The binding of the toxin is slightly off-center such that two of four analogous acidic amino acids are coordinated and the pore is not completely occluded -- nevertheless this toxin blocks approximately 90% of Na^+^ current though the channel ([@bib64]; [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}). The UID interacts with three of the four 'D'-ring amino acids at the mouth of the uniporter's pore and the occlusion of the pore is more extensive than observed for Na~v~1.2 by μ-conotoxin KIIIA ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}). The structure of the holocomplex and its similarity to a pore-blocking toxin complex indicate that MICU1 binding inhibits the flow of Ca^2+^ ions by both obstructing the IMS entrance of the pore and by shielding the negative charge of the 'D' ring through coordination with basic amino acids.

MICU1-MICU2 and Ca^2+^-induced changes {#s2-4}
--------------------------------------

The MICU1-MICU2 portion of the holocomplex is roughly parallelogram shaped, with overall dimensions of approximately 70 × 65 × 35 Å, under resting conditions in which its EF-hand domains are in Ca^2+^-free apo states ([Figure 4A](#fig4){ref-type="fig"}). One of its large relatively-flat surfaces faces and curves slightly toward the membrane due to a slight bend between MICU1 and MICU2 ([Figure 2A](#fig2){ref-type="fig"}). The heterodimer has pseudo twofold symmetry and two analogous interfaces between the subunits ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A--F](#fig4s1){ref-type="fig"}). Hydrophobic amino acids predominate the interfaces, with MICU1-Met 229, MICU1-Phe 383, MICU2-Met 183, and MICU2-Met 337 making analogous and particularly extensive contacts within them ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}). The interfacial residues are conserved in MICU3 ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), which suggests that the neuron-specific MICU1-MICU3 heterodimer has a similar arrangement. As would be expected under resting \[Ca^2+^\] conditions, all four Ca^2+^-binding EF-hand motifs of the MICU1-MICU2 heterodimer ('EF1' and 'EF4' of both subunits) are in the apo state and the heterodimer is superimposable with a previous apo structure of MICU1-MICU2 alone ([@bib38]; [Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}, [Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"}).

From biochemical analysis of the purified protein, and in acoord with a previous report that MICU1-MICU2 has an affinity for cardiolipin ([@bib17]), we found that the heterodimer associates with lipid membranes and lipid nanodiscs that contain cardiolipin ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}, [Figure 4F](#fig4){ref-type="fig"}). This association is independent of Ca^2+^ - both Ca^2+^-free and Ca^2+^-bound heterodimers bind to liposomes. To investigate the conformational change in MICU1-MICU2 upon Ca^2+^ binding, we determined a cryo-EM structure of Ca^2+^-bound MICU1-MICU2 in complex with a lipid nanodisc containing cardiolipin at 3.1 Å resolution ([Figure 4F](#fig4){ref-type="fig"}, [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}, [Figure 4---figure supplement 6](#fig4s6){ref-type="fig"}, and [Table 1](#table1){ref-type="table"}). The side of the heterodimer that associates with the nanodisc is the same as the one that faces the channel ([Figures 1A](#fig1){ref-type="fig"} and [4F](#fig4){ref-type="fig"}). The structure reveals a substantial conformational change upon Ca^2+^ binding that makes the heterodimer more compact and markedly more bent between MICU1 and MICU2 ([Figure 4A--D](#fig4){ref-type="fig"}). Ca^2+^ dependent rearrangements of the EF-hand motifs that involve their helix turn helix elements produce this bend ([Figure 4C--D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Ca^2+^ binding also induces a rotation of the UID relative to MICU1 ([Figure 4E](#fig4){ref-type="fig"}).

![Ca^2+^-dependent changes in MICU1-MICU2.\
(**A**) Cartoon representation of the apo MICU1-MICU2 heterodimer. Gray spheres denote EF-hand residues. (**B**) Overall structure of Ca^2+^-bound MICU1-MICU2. Red spheres indicate bound Ca^2+^ ions. (**C--D**) Bend between MICU1 and MICU2 induced by Ca^2+^ binding (C, apo; D, Ca^2+^-bound). Overall structures are shown from the side with semitransparent molecular surfaces. (**E**) Superposition of apo (gray) and Ca^2+^-bound (green) MICU1 highlighting a rotation of the UID upon Ca^2+^ binding. (**F**) Cryo-EM density depicting the Ca^2+^-bound MICU1-MICU2 complex associated with a lipid nanodisc.](elife-59991-fig4){#fig4}

We sought to understand how Ca^2+^-dependent conformational changes in MICU1-MICU2 might confer Ca^2+^-dependent control to the channel ([Figure 5](#fig5){ref-type="fig"}). Superimposing the Ca^2+^-bound MICU1-MICU2 structure on the UID in the resting holocomplex reveals that the Ca^2+^-induced conformational changes in the heterodimer would place hydrophilic regions of MICU2 within the membrane, which would be highly unfavorable thermodynamically ([Figure 5](#fig5){ref-type="fig"}, middle). Rather than inserting into the membrane, we hypothesize that the bending motion of MICU1-MICU2 acts like a lever against the membrane to pry MICU1 from the mouth of the pore when \[Ca^2+^\]~IMS~ is elevated. Additionally, the Ca^2+^-dependent conformational changes within MICU1 cause a rotation of the UID that could disfavor binding to the channel ([Figure 4E](#fig4){ref-type="fig"}). The conformational changes would dislodge the UID from the blocking conformation, which would allow Ca^2+^ ions to permeate though the channel while \[Ca^2+^\]~IMS~ remains elevated. A dislodged Ca^2+^-bound MICU1-MICU2 complex would be free to bind to the surface of the inner mitochondrial membrane, with which it would associate due to its inherent affintity for membranes, and it may remain proximal the channel as a result of electrostatic interactions with the acidic tail of EMRE ([Figure 5](#fig5){ref-type="fig"}, right) ([@bib59]). When resting \[Ca^2+^\]~IMS~ is restored, a MICU1-MICU2 complex, again devoid of its Ca^2+^ ligands, would resume the blocking configuration ([Figure 5](#fig5){ref-type="fig"}, left, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This mechanism of MICU1-MICU2 control is compatible with the observed dimerization of human MCU-EMRE channels that is due to association of their NTDs -- there is sufficient room for MICU1-MICU2 complexes to associate with both channels of the dimer and to control Ca^2+^ influx through their pores ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

![Proposed mechanism of Ca^2+^-dependent control.\
Left, structure of the holocomplex under resting \[Ca^2+^\]~IMS~ conditions. MCU and EMRE are depicted with cylindrical helices; MICU1 and MICU2 are represented as semitransparent surfaces, with α1 and α2 helices of the UID as ribbons. The lipid membrane (gray) is based upon an atomistic model ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) . The UID blocks the pore (gray tube). Following elevation of \[Ca^2+^\]~IMS~, Ca^2+^ binding causes the MICU1-MICU2 heterodimer to bend (the Ca^2+^-bound MICU1-MICU2 structure is depicted with the channel in the center and right panels). The center panel indicates that bending would dislodge the UID from its receptor site in order to avoid thermodynamically unfavorable interactions of MICU2 with the membrane ('X'). The dislodged Ca^2+^-bound MICU1-MICU2 heterodimer would no longer block the pore, thereby allowing Ca^2+^ permeation through the channel, and it would be free to interact with the membrane (right). Upon the return of resting \[Ca^2+^\], the heterodimer would resume its blocking conformation (left). One MICU1-MICU2 heterodimer is depicted and only one can bind to the receptor on the channel at a time but multiple MICU1-MICU2 heterodimers may be associated with the channel. A brown line depicts a hypothetical interaction of the acidic C-terminus of EMRE with MICU1.](elife-59991-fig5){#fig5}

Discussion {#s3}
==========

With analogy to classical toxin-channel interactions ([@bib28]), the structure of the holocomplex indicates that MICU1-MICU2 prevents mitochondrial Ca^2+^ overload under resting conditions ([@bib26]) and confers Ca^2+^-dependent control by a pore-blocking mechanism. Operating like a regulatable toxin, resting levels of Ca^2+^ permit the blocking conformation while elevated levels disrupt it. A single MICU1-MICU2 heterodimer appears capable of conferring these properties for the simple reason that the receptor site on the channel can accommodate only one UID. However, more than one MICU1-MICU2 heterodimer may be tethered to the channel at any given time, as is indicated by the cryo-EM analysis. Nucleation of more than one heterodimer in the vicinity of the channel would increase the local concentration of MICU1-MICU2 and facilitate a rapid response following restoration of resting cytosolic Ca^2+^ levels. While MICU1-MICU2 visibly interacts with only one EMRE subunit, the displacement of an EMRE subunit (EMRE 4) from the TMD might serve as an additional mechanism to control ion flow since the expression of EMRE is necessary for Ca^2+^ uptake by mitochondria ([@bib26]; [@bib52]; [@bib56]). Additionally, the displacement of an EMRE subunit suggests that the number of EMRE subunits associated with an MCU tetramer can vary, as has been inferred from a recent study ([@bib43]).

During the preparation of this manuscript, cryo-EM structures of a holocomplex comprising human MCU, EMRE, MICU1 and MICU2 subunits in resting and activated \[Ca^2+^\] conditions were reported ([@bib11]). The conclusions of that work are congruous with the present study and validate the proposed mechanism of Ca^2+^-dependent regulation of the uniporter by MICU1-MICU2. Unlike ours, which used lipid nanodiscs, the structures were determined using detergent-solubilized protein, but the absence of a lipid membrane-like environment does not seem to have dramatically influenced the binding of the MICU1-MICU2 regulatory complex to the channel under resting Ca^2+^ conditions ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Interestingly, an additional interaction with the 'D'-ring at the mouth of the pore, involving a loop region of MICU1 (amino acids 258--274) that is disordered in our structure, was observed ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Weak density for this loop in our structure and its disorder in X-ray structures of isolated MICU1 proteins are indications of its flexibility ([@bib58]). A structure of an intact holocomplex at elevated levels of \[Ca^2+^\], which was included in the recent work, indicates that the Ca^2+^-bound MICU1-MICU2 regulatory complex binds adjacent to the pore in essentially the same manner that we propose ([Figure 5](#fig5){ref-type="fig"}, right, and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). The similarities of these studies, which used different experimental conditions, different protein constructs, and MCU-EMRE channels from different species, support a unified understanding of the mechanism of gatekeeping by MICU1-MICU2.

Conclusion {#s3-1}
----------

This work reveals a mechanism for Ca^2+^-dependent control of the mitochondrial calcium uniporter by the MICU1-MICU2 regulatory complex. The mechanism is distinct from the conformational changes that underlie gating, the process by which ion channels permit or prevent ion condution, in many other ion channels -- these often involve changes in the dimensions of their ion conduction pores due to motions of transmembrane α-helices that line these pores, as was first exemplified by structural studies of potassium channels ([@bib27]). Our current understanding of how changes in \[Ca^2+^\]~IMS~ regulate the uniporter comes from the integration of insights from the present work and the large body of preceeding studies. The MICU1-MICU2 complex exists as a heterodimer that is located in the IMS. Under resting cytosolic \[Ca^2+^\] conditions, when the concentration of Ca^2+^ is less than \~0.2 μM, Ca^2+^-binding EF-hand domains within MICU1 and MICU2 are devoid of Ca^2+^ and the heterodimer adopts a Ca^2+^-free conformation that is relatively flat. An inherent affinity of MICU1-MICU2 for lipid membranes and an affinity for a flexible acidic region on the IMS portion of EMRE increase the local concentration of the heterodimer near the MCU/EMRE channel. MCU channels that have multiple EMRE subunits associated with them would tend to have more MICU1-MICU2 complexes nearby, as was inferred from a recent study ([@bib43]). At these low resting concentrations of Ca^2+^, a domain that is specific to MICU1, the uniporter interaction domain (UID), binds to a receptor site at the mouth of the channel's pore and blocks it, with analogy to how protein toxins from venomous organisms block neuronal cation channels. In this blocking conformation, the UID inhibits ion permeation that could otherwise dissipate the mitochondrial electromotive force. Although MICU2 interacts extensively with MICU1, it does not appear to contact the channel directly. When the Ca^2+^ concentration in the IMS becomes elevated, the binding of Ca^2+^ to the EF-hand domains within MICU1 and MICU2 induce conformational changes in the MICU1-MICU2 complex that bend it and cause the UID to rotate. These conformational changes relieve blockage of the pore and thereby permit Ca^2+^ ions to permeate through the channel while \[Ca^2+^\]~IMS~ remains elevated. These processes are reversed upon the restoration of resting \[Ca^2+^\]~IMS~ levels. MICU1-MICU2 heterodimers, and by analogy MICU1-MICU3 heterodimers in neurons, thus confer Ca^2+^-dependent gating to the uniporter by operating like endogenous pore-blocking toxins, the binding of which is governed by Ca^2+^-dependent conformational changes within them. This mechanism represents one of the ways that the mitochondrial Ca^2+^ uniporter, an unusual and intricate ion channel complex, responds to physiological signals to regulate mitochondrial respiration and other cellular processes.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                  Designation                                                                                              Source or reference       Identifiers                                                             Additional\
  (species) or resource                                                                                                                                                                                                                     information
  ------------------------------ -------------------------------------------------------------------------------------------------------- ------------------------- ----------------------------------------------------------------------- -------------
  Gene (*Tribolium castaneum)*   *Tc*MCU                                                                                                  IDT Inc                                                                                           

  Gene (*Tribolium castaneum)*   *Tc*EMRE                                                                                                 IDT Inc                                                                                           

  Gene (*Homo sapiens)*          *Hs*MICU1                                                                                                IDT Inc\                                                                                          
                                                                                                                                          Genewiz, Inc.                                                                                     

  Gene (*Homo sapiens)*          *Hs*MCIU2                                                                                                *IDT Inc*\                                                                                        

  Cell line (*H. sapiens*)       Expi293F                                                                                                 Sigma                     A14527                                                                  

  Cell line (*H. sapiens*)       HEK-293T-MICU1-KO                                                                                        [@bib20]                  DOI: [10.1002/embr.201337946](https://doi.org/10.1002/embr.201337946)   

  Chemical compound, drug        1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine                                                    Avanti Polar Lipids       850757                                                                  

  Chemical compound, drug        1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1\'-rac-glycerol) (sodium salt)                               Avanti Polar Lipids       840457                                                                  

  Chemical compound, drug        *1\',3\'-bis\[1,2-dioleoyl-sn-glycero-3-phospho\]-glycerol (sodium salt)*                                Avanti Polar Lipids       710335                                                                  

  Chemical compound, drug        Polyethylenimine, Linear, MW 25000, Transfection Grade (PEI 25K)                                         Polysciences, Inc         23966--1                                                                

  Chemical compound, drug        Sodium Butyrate                                                                                          Sigma                     8451440100                                                              

  Chemical compound, drug        n-Dodecyl-β-D-maltopyranoside                                                                            Anatrace                  O310S                                                                   

  Chemical compound, drug        (2α,3β,5α,15β,25R)−2,15-dihydroxyspirostan-3-yl O-β\                                                     Cayman Chemical Company   14952                                                                   
                                 -D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→2)-O-\[β-D-xylopyranosyl-(1→4)-β-D-galactopyranoside                                                                                                     

  Chemical\                      Membrane Scaffold Protein 1D1                                                                            Sigma                     M6574                                                                   
  compound, drug                                                                                                                                                                                                                            

  Chemical compound, drug        5-Methyl-2-oxo-4-imidazo\                                                                                Sigma                     D1411                                                                   
                                 lidinehexanoic acid                                                                                                                                                                                        

  Chemical compound, drug        Lipofectamine 3000\                                                                                      Thermo Fisher             L3000008                                                                
                                 Transfection Reagent                                                                                                                                                                                       

  Chemical compound, drug        *Calcium Green−5N, Hexapotassium Salt*                                                                   Thermo Fisher             C3737                                                                   

  Software, algorithm            MotionCor2                                                                                               [@bib65]                  RRID:[SCR_016499](https://scicrunch.org/resolver/SCR_016499)            

  Software, algorithm            CtfFind 4.1.10                                                                                           [@bib51]                  RRID:[SCR_016731](https://scicrunch.org/resolver/SCR_016731)            

  Software, algorithm            RELION 3.0                                                                                               [@bib66]                  [http://www2.mrc-lmb.](http://www2.mrc-lmb.cam.ac.uk/relion)\           
                                                                                                                                                                    [cam.ac.uk/relion](http://www2.mrc-lmb.cam.ac.uk/relion)\               
                                                                                                                                                                    RRID:[SCR_016274](https://scicrunch.org/resolver/SCR_016274)            

  Software, algorithm            SerialEM                                                                                                 [@bib12]                  RRID:[SCR_017293](https://scicrunch.org/resolver/SCR_017293)            

  Software,\                     cryoSPARC v2                                                                                             Structura Biotechnology   <https://cryosparc.com/>\                                               
  algorithm                                                                                                                                                         RRID:[SCR_016501](https://scicrunch.org/resolver/SCR_016501)            

  Software, algorithm            PHENIX                                                                                                   [@bib1]                   <https://www.phenix-online.org/>\                                       
                                                                                                                                                                    RRID:[SCR_014224](https://scicrunch.org/resolver/SCR_014224)            

  Software, algorithm            COOT                                                                                                     [@bib9]                   <https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>\                
                                                                                                                                                                    RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)            

  Software, algorithm            PyMOL                                                                                                    [@bib54]                  <https://pymol.org/2/>\                                                 
                                                                                                                                                                    RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)            

  Software, algorithm            UCSF Chimera                                                                                             [@bib46]                  <https://www.cgl.ucsf.edu/chimera>\                                     
                                                                                                                                                                    RRID:[SCR_004097](https://scicrunch.org/resolver/SCR_004097)            

  Software, algorithm            GraphPad Prism 7                                                                                         GraphPad Software         <https://cryosparc.com/>\                                               
                                                                                                                                                                    RRID:[SCR_016501](https://scicrunch.org/resolver/SCR_016501)            

  Software, algorithm            Hole                                                                                                     [@bib55]                  <http://www.holeprogram.org>                                            

  Software, algorithm            UCSF ChimeraX                                                                                            Goddardnet al. 2018       <https://www.cgl.ucsf.edu/chimerax/>                                    

  Others                         QUANTIFOIL R1.2/1.3 holey carbon grids                                                                   Quantifoil                                                                                        

  Others                         FEI Vitrobot Mark IV                                                                                     FEI Thermo Fisher                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Holocomplex preparation {#s4-1}
-----------------------

Tribolium castaneum MCU (*Tc*MCU; UniProt accession: TcasGA2_TC013837) and Tribolium castaneum EMRE (*Tc*EMRE; UniProt accession: TcasGA2_TC012057) were selected as candidates for structural and functional studies from among \~30 metazoan MCU orthologs that were evaluated using fluorescence-detection size-exclusion chromatography (FSEC) screening technique using HEK-293 cells ([@bib14]; [@bib60]) (cells obtained from and validated by Invitrogen, tested negative for mycoplasma). cDNA encoding *Tc*MCU (residues 174--359, with a C-terminal Strep II tag) and *Tc*EMRE (residues 29--90) genes were chemically synthesized (IDT Inc), each cloned into a mammalian cell expression vector ([@bib14]) to encode proteins with an N-terminal Venus tag and an intervening PreScission protease cleavage site. The plasmids were co-transfected into Expi293 cells (obtained from and validated by Invitrogen, tested negative for mycoplasma) using PEI25k reagents (Polysciences, Inc) for transient expression. Briefly, 0.4 mg *Tc*MCU plasmid, 0.6 mg *Tc*EMRE plasmid and 3 mg PEI25k were mixed with 100 ml OptiMEM media (Invitrogen), incubated at room temperature for 20 min, and combined with approximately 3 × 10^9^ Expi293 cells in 1 L of Expi293 media (Invitrogen). After incubation of the cells at 37° C for 16 hr with shaking (125 rpm), 10 mM sodium butyrate (Sigma-Aldrich) was added, and the cells were cultured at 30° C for an additional 48 hr before harvest.

The pellet from 1 L of cell culture was resuspended in 100 ml lysis buffer (40 mM HEPES pH 7.5 200 mM NaCl, 0.15 mg/ml DNase I, 1.5 μg/ml Leupeptin, 1.5 μg/ml Pepstatin A, 1 mM AEBSF, 1 mM Benzamidine, 1 mM PMSF and 1:500 dilution of Aprotinin), and then solubilized by adding n-Dodecyl-β-D-Maltopyranoside (DDM, Anatrace) to a final concentration of 1% while stirring at 4°C for 1 hr. Solubilized proteins were separated from the insoluble fraction by centrifugation at 60,000 g for 1 hr and the supernatant was filtered through a 0.22 μm polystyrene membrane (Millipore). 2 ml GFP nanobody resin was added and the sample was rocked at 4°C for 1 hr ([@bib22]). The beads were washed with 100 ml of 20 mM HEPES pH7.5, 200 mM NaCl and 1 mM digitonin, eluted by adding PreScission protease (0.1 mg, 3 hr at 4°C, supplemented with 1 mM DTT), and further purified by size-exclusion chromatography (Superose 6 Increase, 10/300 GL column, GE Healthcare) equilibrated with 20 mM HEPES pH 7.5, 150 mM NaCl and 1 mM digitonin. The peak fractions were pooled, concentrated to OD~280~ \~1.0 (100 kDa cutoff;\~0.5 ml), mixed with 0.2 ml lipid/DDM mixture (17 mM DDM, 10 mM lipids: POPE (Avanti) : POPG (Avanti) : cardiolipin (18:1, Avanti) with a 2:2:1 wt ratio) and 0.25 ml nanodisc scaffold protein (MSP1D1, Sigma, 5 mg/ml, in buffer containing 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.5 mM EDTA and 5 mM sodium cholate). After 1 hr incubation at 4°C,\~300 mg wet Bio-Beads SM2 (Bio-Rad) were added and the sample was rotated at 4°C for \~16 hr to remove detergent. To remove excess EMRE and empty nanodiscs, the sample was further purified by Strep-Tactin Sepharose (Qiagen). Briefly, the nanodisc sample was bound to 0.3 ml Strep-Tactin Sepharose with rotation at 4°C for 30 min, washed with 10 ml buffer (20 mM HEPES pH 7.5, 150 mM NaCl), and eluted with 2 ml buffer (20 mM HEPES pH 7.5, 150 mM NaCl and 5 mM d-Desthiobiotin).

MICU1 and MICU2 were expressed as a single polypeptide with a linker connecting the two proteins. The construct consists of human MICU1 (residues 94--476) connected to human MICU2 (residues 51--434). Unstructured regions of the polypeptide and a Ser-Asn peptide comprise a 44 amino acid linker between the structured regions of MICU1 and MICU2 (spanning \~32 Å in the structure). The expression construct was obtained in a stepwise manner. cDNA for human MICU1 (encoding residues 94--476) was amplified from a normal human brain cDNA library (BioChain, Inc) and ligated into the XhoI and EcoRI sites of an expression plasmid ([@bib14]) to contain an N-terminal Venus tag and PreScission protease cleavage site (Venus-PreScission-MICU1). cDNA encoding human MICU2 (amino acids 51--434) was amplified in the same manner and inserted into that plasmid, using MfeI/EcoRI and SalI restriction sites, to yield the final expression plasmid (Venus-PreScission-MICU1-MICU2). The expression and purification of MICU1-MICU2 followed a similar procedure to that for MCU and EMRE. The pellet from 0.3 L of cell culture (prepared using the same growth conditions as described above) was resuspended in 20 ml lysis buffer, DDM was added to a final concentration of 1%, and the sample was agitated at 4°C for 1 hr. The sample was clarified by centrifugation (60,000 g for 1 hr, 4°C) and the supernatant was filtered through a 0.22 μm polystyrene membrane (Millipore). 2 ml GFP nanobody resin was added and the sample was rocked at 4°C for 1 hr. The beads were washed with 100 ml buffer (20 mM HEPES pH 7.5, 500 mM NaCl and 1 mM DDM), the MICU1-MICU2 protein was eluted using 0.1 mg PreScission protease (16 hr, 4°C, supplemented with 1 mM DTT), and the sample was further purified by SEC (Superose 6 Increase, 10/300 GL) in 20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA and 1 mM DDM. The peak fractions corresponding to the MICU1-MICU2 protein were pooled and concentrated to 1 mg/ml (Vivaspin 2, 100 kDa cutoff). To remove DDM,\~300 mg wet Bio-Beads SM2 (Bio-Rad) were added and the sample was rotated (4°C, 3 hr). Purified MICU1-MICU2 protein was then combined with the purified with MCU-EMRE-nanodisc sample (using a molar ratio of 2 MICU1-MICU2 : one channel, 4°C, 30 min.) and the complex was purified by SEC (Superose 6 Increase, 10/300 GL column, GE Healthcare) in 20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM EGTA. The peak fractions were collected, concentrated to 1 mg/ml (Vivaspin 2, 100 kDa cutoff), and used immediately for cryo-EM grid preparation. From the Maxchelator software ([@bib53]), and assuming a typical trace concentration of Ca^2+^ in buffer components (\~2--5 μM), we estimate \[Ca^2+^\]~free~ \~100 pM in the sample.

Preparation of Ca^2+^-bound MICU1-MICU2 bound to nanodiscs {#s4-2}
----------------------------------------------------------

To form empty nanodiscs, 0.2 ml of a lipid/DDM mixture (17 mM DDM, 10 mM lipids: POPE: POPG: cardiolipin \[18:1\] with a 2:2:1 wt ratio) was combined with 0.25 ml nanodisc scaffold protein (MSP1D1, Sigma, 5 mg/ml). After 1 hr incubation on ice, 0.4 ml buffer (20 mM HEPES pH 7.5, 150 mM NaCl) and \~200 mg wet Bio-Beads SM2 (Bio-Rad) were added, the sample was rotated at 4°C for \~16 hr to remove detergent, and then it was purified by size-exclusion chromatography (Superose 6 Increase, 10/300 GL column, GE Healthcare; equilibrated with 20 mM HEPES pH 7.5, 150 mM NaCl). The peak fractions were pooled, combined with purified MICU1-MICU2 protein (using a molar ratio of 1 MICU1-MICU2 : 1.5 nanodisc scaffold protein; 4°C, 30 min.), and the complex was purified by size-exclusion chromatography (Superose 6 Increase, 10/300 GL column, GE Healthcare; equilibrated with 20 mM HEPES pH 7.5, 150 mM NaCl). The peak fractions were collected, concentrated to 0.5 mg/ml (Vivaspin 2, 100 kDa cutoff), CaCl~2~ was added to a final concentration of 1 mM, and the sample was used for cryo-EM grid preparation.

EM sample preparation and data acquisition {#s4-3}
------------------------------------------

For all samples, 4 μl of purified protein was applied to glow-discharged (10 s) Quantifoil R 1.2/1.3 grids (Au 400; Electron Microscopy Sciences) and plunge-frozen in liquid nitrogen-cooled liquid ethane, using a Vitrobot Mark IV (FEI) operated at 4°C with a blotting time of 2--3 s (blot force 0) with 100% humidity. Grids were clipped and loaded into a 300 keV Titan Krios microscope (FEI) equipped with a Gatan K3 direct electron detector. Micrographs were collected in super-resolution mode (pixel size of 0.532 Å) with a nominal defocus range of −1.0 to −3.0 μm. The dose rate was 20 electrons/pixel/s. Images were recorded for 4 s with 0.1 s subframes (40 total frames), corresponding to a total dose of 71 electrons per Å^2^.

Image processing and model building {#s4-4}
-----------------------------------

For the holocomplex, 21,115 movie stacks were gain-corrected, twofold binned (using a pixel size of 1.1 Å), motion corrected, and dose weighted using MotionCor2 ([@bib65]). Contrast transfer function (CTF) estimates were performed in CTFFIND4 using non-dose weighted micrographs ([@bib51]). 19,972 micrographs with CtfMaxResolution values better than 4 Å were selected for further processing. 17,440,131 particles were picked automatically and extracted (using a binned pixel size of 4.4 Å) using RELION 3.0 ([@bib66]). These particles were then imported into cryoSPARC v.2 ([@bib49]). The particles were cleaned-up by one round of Ab initio reconstruction and two rounds of heterogeneous refinement. 2,388,041 particles from the best classes were selected and subjected to non-uniform refinement in cryoSPARC v.2, which yielded a reconstruction at \~9.4 Å overall resolution. The refined particles were then centered and re-extracted in RELION 3.0 with a pixel size of 2.2 Å, imported into cryoSPARC v.2 for another two rounds of heterogeneous refinement. 761,813 particles from the best classes were chosen and used for non-uniform refinement in cryoSPARC v.2, which yielded a reconstruction at \~4.4 Å overall resolution. The refined particles were centered and re-extracted in RELION 3.0 with a pixel size of 1.1 Å, and imported into cryoSPARC v.2 for another two rounds of heterogeneous refinement. 510,869 particles from the best class were subjected into non-uniform refinement in cryoSPARC v.2, and this yielded a reconstruction at 3.9 Å overall resolution. One round of Bayesian polishing in Relion 3.0 improved the resolution to 3.6 Å. After local CTF refinement in cryoSPARC v.2 and another round of Bayesian polishing in RELION 3.0, the particles were further classified by heterogeneous refinement in cryoSPARC v.2 and 3D classification (focused classification on the TMD) in RELION 3.0. 350,160 particles from the classes with a more well-defined TMD region were chosen and subjected to 3D auto refinement in RELION 3.0. Postprocessing in RELION 3.0 (using a calibrated pixel size of 1.064 Å) yielded the final reconstruction at 3.3 Å. All resolution estimates are based on gold-standard Fourier shell correlation (FSC) calculations. Estimation of the local resolution of the map was performed using Resmap ([@bib25]).

For the structure of MICU1-MICU2 bound to nanodiscs and in 1 mM Ca^2+^, 4675 movie stacks were gain-corrected, twofold binned (using a pixel size of 1.064 Å), motion corrected, and dose weighted using MotionCor2 ([@bib65]). Contrast transfer function (CTF) estimates were performed in CTFFIND4 using non-dose weighted micrographs ([@bib51]). 4280 micrographs with CtfMaxResolution values better than 5 Å were selected for further processing. Particles were picked using Gaussian blob or 2D template-based autopicking and extracted (3,957,711 or 4,397,598 particles, respectively, with a binned pixel size of 2.128 Å) using RELION 3.0 ([@bib66]). The two sets of particles were then imported into cryoSPARC v.2 to do processing separately ([@bib49]). For the particles from Gaussian autopicking, the particles were cleaned-up by one round of Ab initio reconstruction and three rounds of heterogeneous refinement (using seven classes), and 135,522 particles from the best classes were selected and subjected to non-uniform refinement in cryoSPARC v.2, which yielded a reconstruction at \~4.3 Å overall resolution. For the particles picked using 2D templates, particles were cleaned-up by three rounds of heterogeneous refinement and 152,512 particles from the best classes were selected and subjected to non-uniform refinement in cryoSPARC v.2, which yielded a reconstruction at \~4.3 Å overall resolution. The two sets of particles were then merged, centered and re-extracted in RELION 3.0 with a pixel size of 1.064 Å, and duplicate particles or particles with CtfMaxResolution values worse than 4 Å were removed. The resulting 181,934 particles were imported into cryoSPARC v.2 for additional rounds of heterogeneous refinement. 142,055 particles from the best classes were chosen and used for non-uniform refinement in cryoSPARC v.2, which yielded a reconstruction at \~3.7 Å overall resolution. One round of Bayesian polishing in Relion 3.0 improved the resolution to 3.5 Å. After another round of Bayesian polishing in RELION 3.0, followed by CTF refinements (global and local) and several rounds of heterogeneous refinement in cryoSPARC v.2 (139,974 particles were selected), the resolution was improved to 3.2 Å. The selected particles were subjected to additional Bayesian polishing in RELION 3.0, followed by CTF refinement (global and local) and heterogeneous refinement in cryoSPARC v.2 (yielding 115,687 particles), which yielded the final reconstruction at 3.1 Å resolution. All resolution estimates are based on gold-standard Fourier shell correlation (FSC) calculations. Estimation of the local resolution of the map was performed using Resmap ([@bib25]).

The atomic model of the holocomplex was manually built and refined in real space using the COOT software ([@bib9]). A cryo-EM structure of *Tc*MCU-EMRE ([@bib60]) and X-ray structures of MICU1 and MICU2 ([@bib19]; [@bib58]) were used as starting points. Further real-space refinement was carried out in PHENIX ([@bib1]), to yield the final model ([Table 1](#table1){ref-type="table"}). Structural figures were prepared with Pymol ([pymol.org](https://pymol.org/2/)) ([@bib54]), Chimera ([@bib46]), ChimeraX ([@bib13]), and HOLE ([@bib55]).

Mitochondrial Ca^2+^ uptake experiments {#s4-5}
---------------------------------------

cDNA encoding full-length wild type human MICU1 was amplified from a normal human brain cDNA library (BioChain, Inc), whereas an EF-hand mutant MICU1 gene with mutations abolishing Ca^2+^ binding (D231A, E244K, D421A, E432K) was chemically synthesized (Genewiz, Inc). Both genes were sub-cloned into the XhoI and EcoRI sites of a mammalian expression vector that includes a C-terminal Rho-1D4 antibody tag ([@bib3]; [@bib31]). Mutations F106A, R117A, Y121A, K126A and R129A were generated by PCR using mutagenic primers on the background of the EF-hand mutant and verified by sequencing. MICU1 knockout cells, derived from human HEK-293T cells and generously provided by V. Mootha ([@bib20]) (authenticated using mitochondrial Ca^2+^ uptake assays ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}); tested negative for mycoplasma), were grown in DMEM media (Invitrogen). 3 μg of each plasmid was transfected into \~1.5×10^6^ of these cells using Lipofectamine 3000 (Invitrogen), and the cells were grown for an additional 24 hr at 37°C before use.

The mitochondrial Ca^2+^ uptake assay using these cells was performed as described ([@bib3]), with slight modifications. Briefly, after addition of 1 μM Calcium Green-5N (Life Technologies) and 0.05 mM digitonin, 20 μM CaCl~2~ (from a 4 mM stock in water) was added at the 100 s time point to initiate mitochondrial Ca^2+^ uptake. The data plotted in [Figure 3E](#fig3){ref-type="fig"} were obtained from Ca^2+^ uptake curves (e.g. [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}) in the following manner. A rate of Ca^2+^ uptake (uptake_rate) was defined as the slope of a linear fit of the Ca^2+^ uptake curve between 111 and 135 s. Relative uptake was then defined as: (uptake_rate~UID-mutant~ -- uptake_rate~EF-hand-mutant~) / (uptake_rate~WT~ -- uptake_rate~EF-hand-mutant~), where 'WT' represents wild type MICU1, 'EF-hand-mutant' represents MICU1 bearing the EF-hand mutations, and 'UID-mutant' represents a given mutation of the UID on the background of the EF-hand-mutant. From this equation, a relative uptake of 1 indicates a mitochondrial Ca^2+^ uptake rate equivalent to that observed for wild type MICU1 and a relative uptake of 0 indicates a mitochondrial Ca^2+^ uptake rate equivalent to that observed for the EF-hand-mutant.

Assessing the association of MICU1-MICU2 with liposomes {#s4-6}
-------------------------------------------------------

To prepare liposomes, 5 mg of dried lipids (POPE: POPG: cardiolipin \[18:1\] with a 2:2:1 wt ratio) was mixed with 1 ml reconstitution buffer (20 mM HEPES pH 7.5, 150 mM NaCl) and the sample was sonicated until homogeneous (\~2 min). 20 μl of purified MICU1-MICU2 protein (0.5 mg/ml) was added to 80 μl of liposomes or 80 μl of reconstitution buffer, each supplemented with a final concentration of 1 mM CaCl~2~ or with 1 mM EGTA and 1 mM EDTA. As a negative control, 20 μg of purified green fluorescent protein was combined with liposomes or buffer in the same manner. After incubation for 30 min at 4°C, the samples were centrifuged at 140,000 g (30 min at 4°C). The supernatants were removed and the pellets were resuspended for SDS-PAGE analysis (by resuspending the pellets in 40 μl reconstitution buffer, adding 40 μl SDS-PAGE loading buffer containing 100 mM DTT, and analyzing 20 μl by Coomassie-stained SDS-PAGE).

Materials availability {#s4-7}
----------------------

Correspondence and requests for materials should be addressed to SBL ([Longs\@mskcc.org](https://www.mskcc.org/research/ski/labs/stephen-long)).
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Data availability {#s7}
=================

The atomic coordinates and EM maps have been deposited in the Protein Data Bank ([www.rcsb.org](http://www.rcsb.org)) and the EMDB ([www.ebi.ac.uk/pdbe/emdb/](http://www.ebi.ac.uk/pdbe/emdb/)): PDB ID 6XQN, EMDB ID EMD-22290 (holocomplex in low Ca2+); PDB ID 6XQO, EMDB ID EMD-22291 (Ca2+-bound MICU1-MICU2 heterodimer).

The following datasets were generated:

WangCJacewiczADelgadoBDBaradaranRLongSB2020holocomplex in low Ca2+Electron Microscopy Data BankEMD-22290

WangCJacewiczADelgadoBDBaradaranRLongSB2020holocomplex in low Ca2+RCSB Protein Data Bank6XQN

WangCJacewiczADelgadoBDBaradaranRLongSB2020Ca2+-bound MICU1-MICU2 heterodimerElectron Microscopy Data BankEMD-22291

WangCJacewiczADelgadoBDBaradaranRLongSB2020Ca2+-bound MICU1-MICU2 heterodimerRCSB Protein Data Bank6XQO
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This manuscript reports cryo-EM structures of the mitochondrial calcium uniporter (MCU) in complex with the auxiliary subunit EMRE and the MICU1/MICU2 regulatory heterodimer. The authors also present structures of Ca^2+^-bound MICU1/MICU2 interacting with nanodiscs. Together, these structures provide remarkable insight into the mechanism by which the MICU1/MICU2 heterodimer gates the pore, occluding the mouth of the pore and preventing flux under resting (low) calcium conditions. The authors draw an analogy to pore-blocking toxins of potassium and sodium channels that inhibit by physically occluding the ion permeation pathways of these channels. The authors suggest a mechanism by which a conformational change in MICU1/MICU2 upon Ca^2+^ binding disrupts the binding to the MCU pore, displacing it to the membrane to support ion conduction. This is a very strong and impressive manuscript. The analysis of the structures is rigorous and well-supported by the literature and the transport data in the manuscript. The work is of high quality, expands and strongly enhances the results for human holocomplex recently published in Nature (Fan et al., 2020). The manuscript itself is clearly written and we think it should be published as soon as possible.

**Decision letter after peer review:**

Thank you for submitting your article \"Structures reveal gatekeeping of the mitochondrial Ca^2+^ uniporter by MICU1-MICU2\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Kenton Swartz as the Reviewing Editor and Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Alexander Sobolevsky (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

This manuscript from Stephen Long\'s lab presents structures of the mitochondrial calcium uniporter (MCU) in complex with the auxiliary subunit EMRE and the MICU1/MICU2 regulatory heterodimer. The authors also present structures of Ca^2+^-bound MICU1/MICU2 interacting with nanodiscs. Together, these structures provide insight into the mechanism by which the MICU1/MICU2 heterodimer gates the pore, occluding the mouth of the pore and preventing flux under resting (low) calcium conditions. The authors draw an analogy to sodium channel inhibition by the pore-binding conotoxin KIIIA. The authors suggest a mechanism by which a conformational change in MICU1/MICU2 upon Ca^2+^ binding disrupts the binding to the MCU pore, displacing it to the membrane. This is a very strong and impressive manuscript. The analysis of the structures is rigorous and well-supported by the literature and the transport data in the manuscript. The work is of high quality, expands and strongly enhances the results for human holocomplex recently published in Nature (Fan et al., 2020). The manuscript itself is clearly written and we think it should be published as soon as possible.

Essential revisions:

1\) The manuscript did not comment on the function of the beetle MCU(δ NTD)-EMRE channel core and whether it showed MICU1-dependent Ca^2+^ regulation. Would it be possible to show that the construct used was actually functional?

2\) The MICU1-MICU2 concatemer consists of human MICU1 (residues 94-476) connected to MICU2 (residues 51-434) by a 44 amino acid linker between the structured regions of MICU1 and MICU2. Considerable portions of both MICU1 and MICU2 were removed from the construct and an artificial linker was introduced to connect MICU1 and MICU2. Do the authors have data showing that this concatemer actually functions like the native MICU1-MICU2 heterodimer.

3\) The authors suggested that the more bent MICU1-MICU2-Ca^2+^ acts like a lever against the membrane to pry MICU1 from the mouth of the pore. However, Figure 5 (right panel) also indicates that the MICU1-MICU2 dimer would need to rotate 180 degrees to unblock the channel. Please consider revising Figure 5 and also Figure 5---figure supplement 3. Another point regarding the lever mechanism. If MCU-EMRE resides in a curved membrane as indicated by the structure of the channel dimer (Figure 5---figure supplement 3), the bent MICU1-MICU2-Ca^2+^ may not be able to force MICU1 out of the mouth of the pore. Alternative/additional discussion should be added to address this possibility.

4\) In high calcium conditions, MICU1-MICU2 heterodimers form dimers through MICU2-MICU2 interface as part of the recently published O-shaped uniplex (Fan et al., 2020). Is this dimer of heterodimers formation observed (may be in a small subset of particles) for the calcium-bound MICU1-MICU2 heterodimer in the present study?

5\) Is it possible to map the second MICU1-MICU2 heterodimer binding site on the MCU-EMRE-MICU1-MICU2 holocomplex observed in 2% of channel assemblies? Even at low resolution, it might be interesting to analyze this second binding interface. Would this interface be the same/different/overlap with the putative interface between MICU1 and MCU-EMRE in the O-shaped uniplex? Depending on the answer, it might be possible to speculate about the physiological relevance of this interface.
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Author response

> Essential revisions:
>
> 1\) The manuscript did not comment on the function of the beetle MCU(δ NTD)-EMRE channel core and whether it showed MICU1-dependent Ca^2+^ regulation. Would it be possible to show that the construct used was actually functional?

Thank you for these comments. As mentioned in the revised manuscript, we shown in a recent study from our laboratory (Wang, Baradaran and Long, 2020) that the MCU/EMRE constructs used for structural studies catalyze Ca^2+^ uptake into human mitochondria (Supplementary Figure 1B of that manuscript, trace labeled "*Tc*MCU~ΔNTD~ and EMRE coexpression\"). Preliminary functional studies from our laboratory suggest that human MICU1-MICU2 confers regulation to *Tc*MCU/EMRE in a normal manner; the data will be published when they are complete. Several other lines of evidence support this conclusion. Ming-Feng Tsai's laboratory has shown that human MICU1 can bind to MCU/EMRE channels from numerous metazoan species (Phillips, Tsaiand Tsai, 2019). Structural comparisons show that the UID receptor surface on the TcMCU/EMRE channel is indistinguishable from that of human MCU/EMRE (Figure 1---figure supplement 6). Sequence alignments indicate that the residues of human MICU1 that interact with TcMCU/EMRE in the structure are identically conserved in beetle MICU1 (Figure 3---figure supplement 2). Finally, the transport data presented in our manuscript support the conclusion that human MICU1-MICU2 regulatory complexes bind to human MCU/EMRE channels in the manner observed.

> 2\) The MICU1-MICU2 concatemer consists of human MICU1 (residues 94-476) connected to MICU2 (residues 51-434) by a 44 amino acid linker between the structured regions of MICU1 and MICU2. Considerable portions of both MICU1 and MICU2 were removed from the construct and an artificial linker was introduced to connect MICU1 and MICU2. Do the authors have data showing that this concatemer actually functions like the native MICU1-MICU2 heterodimer.

Thank you for this comment. Preliminary data from both mitochondrial Ca^2+^ uptake studies and in vitro reconstitution experiments, as mentioned in response to Comment 1, suggest that the MICU1-MICU2 concatemer functions like a native MICU1-MICU2 heterodimer. In support of this, we show that the MICU1-MICU2 concatemer adopts the same structural conformation as other available structures of MICU1/MICU2 complexes (Figure 4---figure supplement 6). The effects of mutations within UID of human MICU1 on mitochondrial Ca^2+^ uptake rates (Figure 3E) support the conclusion that native MICU1-MICU2 heterodimer complexes bind to MCU/EMRE channels in the manner observed.

> 3\) The authors suggested that the more bent MICU1-MICU2-Ca^2+^ acts like a lever against the membrane to pry MICU1 from the mouth of the pore. However, Figure 5 (right panel) also indicates that the MICU1-MICU2 dimer would need to rotate 180 degrees to unblock the channel. Please consider revising Figure 5 and also Figure 5---figure supplement 3. Another point regarding the lever mechanism. If MCU-EMRE resides in a curved membrane as indicated by the structure of the channel dimer (Figure 5---figure supplement 3), the bent MICU1-MICU2-Ca^2+^ may not be able to force MICU1 out of the mouth of the pore. Alternative/additional discussion should be added to address this possibility.

Thank you for these comments regarding the proposed mechanism. With regard to the right panel of Figure 5, we do not intend to imply that the "MICU1-MICU2 dimer would need to rotate 180 degrees to unblock the channel". Bending of the MICU1-MICU2 dimer itself would relieve block, and we have attempted to clarify our thinking in this regard. However, because Ca^2+^-bound MICU1-MICU2 associates with lipid membranes (as evidenced by our studies using nanodiscs and liposomes), we hypothesize that the dimer would usually be associated with the surface of the inner mitochondrial membrane when Ca^2+^ levels are elevated. Due to tethering to EMRE, we propose that it would typically bind to the region of the membrane adjacent to the channel in a manner similar to what is shown in the right panel of Figure 5. In the revised manuscript we also point out that Ca^2+^-binding causes the UID to rotate with respect to the remainder of MICU1 (Figure 4E) and that this might also reduce its affinity for the channel. With respect to the situation in which channel dimers may reside in a curved membrane: We still posit that the bent MICU1-MICU2-Ca^2+^ would be able to force MICU1 out of the mouth of the pore because the membrane would need to be considerably more bent than it is in the channel dimer complex to prevent this effect. However, it is conceivable that membrane curvature could modulate the affinity of the UID for its receptor, and one could imagine that this may modulate Ca^2+^ uptake by the channel in regions of high curvature (e.g. cristae). In the revised manuscript, we draw more attention to the Ca^2+^-induced rotation of the UID as an additional means by which the affinity of the UID may be reduced when \[Ca^2+^}~IMS~ is elevated.

> 4\) In high calcium conditions, MICU1-MICU2 heterodimers form dimers through MICU2-MICU2 interface as part of the recently published O-shaped uniplex (Fan et al., 2020). Is this dimer of heterodimers formation observed (may be in a small subset of particles) for the calcium-bound MICU1-MICU2 heterodimer in the present study?

2D classification of the Ca^2+^-bound MICU1-MICU2 dataset reveals approximately 3% of particles containing two MICU1-MICU2 complexes associated with each other (Figure 4---figure supplement 1B). These particles display an orientation preference such that "top views" predominate. This orientation preference prevented us from generating an accurate 3D reconstruction. However, these 2D class averages are strikingly similar to projections of the dimer of MICU1-MICU2 heterodimers from the high \[Ca^2+^\] form of the human holocomplex structure (Figure 4---figure supplement 1C). This similarity suggests that a portion of the MICU1-MICU2 heterodimers do form dimers through MICU2:MICU2 interfaces in our cryo-EM sample. However, because MICU1 and MICU2 have similar structures, we cannot exclude the possibility that some fraction of MICU1-MICU2 heterodimers form dimers through MICU1:MICU1 interfaces in our sample as well.

> 5\) Is it possible to map the second MICU1-MICU2 heterodimer binding site on the MCU-EMRE-MICU1-MICU2 holocomplex observed in 2% of channel assemblies? Even at low resolution, it might be interesting to analyze this second binding interface. Would this interface be the same/different/overlap with the putative interface between MICU1 and MCU-EMRE in the O-shaped uniplex? Depending on the answer, it might be possible to speculate about the physiological relevance of this interface.

Thank you for these comments. We have generated a 3D reconstruction from the \~2% of particles of the holocomplex dataset at low Ca^2+^ that contains two MICU1-MICU2 heterodimers per channel assembly (Figure 1---figure supplement 3C). As described in the revised manuscript, although this structure is determined at low (\~10 Å resolution), key features are visible. One MICU1-MICU2 heterodimer occupies the site observed in the high-resolution holocomplex structure and its association with the MCU/EMRE channel is indistinguishable from that structure. Density for the other MICU1-MICU2 heterodimer, which is considerably weaker, is positioned to the side, next to channel. For clarity, we note that, to our knowledge, a structure of an "O-shaped uniplex" that contains two channels and two MICU1-MICU2 heterodimers has not been determined under resting (low) levels of Ca^2+^. However, a speculative model of such a complex is shown in Figure 5---figure supplement 2. The second MICU1-MICU2 heterodimer within the low-resolution structure could potentially occupy a similar location as the second MICU1-MICU2 heterodimer in the O-shaped uniplex model. However, we prefer to not speculate on the potential physiological relevance of this, partly because we have shown that MICU1-MICU2 complexes have an affinity for membranes and this may be the reason for an additional MICU1-MICU2 complex bound in a small percentage of the particle images.
